2023
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriod
2021
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, Borg R, Schulz WL, de Oliveira RD, da Silva PV, de Castro DB, de Souza Sampaio V, de Albuquerque BC, Ramos TCA, Fraxe SHH, da Costa CF, Naveca FG, Siqueira AM, de Araújo WN, Andrews JR, Cummings DAT, Ko AI, Croda J. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. The Lancet Regional Health - Americas 2021, 1: 100025. PMID: 34386791, PMCID: PMC8310555, DOI: 10.1016/j.lana.2021.100025.Peer-Reviewed Original ResearchSymptomatic SARS-CoV-2 infectionSARS-CoV-2 infectionTwo-dose scheduleTest-negative case-control studyEffectiveness of CoronaVacCase-control studyHealthcare workersVariant transmissionVaccine doseFirst doseSecond doseSample collection dateSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsDose of CoronaVacTest-negative studiesVaccine effectiveness estimatesEffectiveness of vaccinesRT-PCR testingCase-control pairsRT-PCR testMunicipal Health SecretarySARS-CoV-2 samplesNon-pharmaceutical interventionsPeriod 14 daysUnvaccinated individuals